サウスカロライナにおける喘息の臨床試験
サウスカロライナ内の拠点で、喘息に関する9件の研究が参加者を募集しています。
公式研究テキスト（英語）
A Study to Compare Safety of 4 Weeks Exposure to Propellants Hydrofluoroalkane 1,1-difluoroethane (HFA-152a) and HFA-1,1,1,2-tetrafluoroethane (134a)
- GSK Investigational Site, Spartanburg
- GSK Investigational Site, Spartanburg
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/30更新 · NCT07645248A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma
- GSK Investigational Site, Charleston
被験者募集中第3相
12歳〜17歳 · 全性別 · 2026/09/30更新 · NCT05757102Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroids
- Research Site, Rock Hill
被験者募集中第2相
18歳〜75歳 · 全性別 · 2026/09/25更新 · NCT06932263ENV-294 for Moderate-to-Severe Asthma: A 12-Week Study in Adults
- Enveda Investigative Site, North Charleston
被験者募集中第2相
18歳〜75歳 · 全性別 · 2026/09/24更新 · NCT07301255A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-2)
- Research Site 16, Rock Hill
被験者募集中第3相
12歳〜80歳 · 全性別 · 2026/09/22更新 · NCT07359846A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma
- Clinical Research of Rock Hill, Rock Hill
被験者募集中第2相
18歳〜70歳 · 全性別 · 2026/09/22更新 · NCT06977581A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma
- Teva Investigational Site 12107, Rock Hill
被験者募集中第3相
12歳以上 · 全性別 · 2026/08/31更新 · NCT06664619Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma
- Research Site, Charleston
被験者募集中第3相
12歳〜17歳 · 全性別 · 2026/08/13更新 · NCT06307665A Clinical Study to Evaluate the Efficacy and Safety of Frevecitinib (KN-002) in Patients With Severe Asthma
- Research site, Rock Hill
被験者募集中第2相
18歳〜75歳 · 全性別 · 2026/07/28更新 · NCT07532265ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。